Summary

The planned lab will combine technologies from Abcam, Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies and Molecular Devices. Danaher says the system is intended to accelerate affinity-reagent discovery by up to eight times and increase reagent generation as it scales.

Why it matters

The project is a concrete move toward autonomous scientific infrastructure, where models select experiments and robotics execute and verify them.

Sources